Who Owns Lamisil?

• Parent Company: Haleon plc
• Ownership Type: Wholly owned
• Acquisition Year: 2014
• Company Type: Publicly Traded
• Stock Ticker: LSE: HLN

• Founded: 1991
• Founders: Sandoz (now Novartis)
• Acquired by Haleon plc: 2014

• Founded: 2022
• Headquarters: Weybridge, Surrey, United Kingdom
• Company Type: Publicly Traded
• Stock: LSE: HLN
• Revenue: approximately £10.2 billion (FY2025)
• Employees: Approximately 24,000

Visit Haleon plc website

• Headquarters: Weybridge, United Kingdom
• Manufacturing / Operations: United Kingdom, United States, Switzerland, Various international locations

Lamisil operates under Haleon's comprehensive sustainability framework, focusing on responsible pharmaceutical manufacturing, environmental stewardship, and ethical business practices in the antifungal medication market. As a leading over-the-counter antifungal treatment, Lamisil benefits from Haleon's commitment to health inclusivity, environmental responsibility, and sustainable healthcare solutions.

Haleon ESG Leadership: Lamisil benefits from Haleon's exceptional ESG performance, which received an MSCI ESG Rating of AA in 2025, placing the company among the top performers in the consumer healthcare sector. Haleon maintained Prime status on the ISS ESG Corporate Rating with a C+ rating in June 2025 and scored 72 out of 100 in the S&P 2024 Global Corporate Sustainability Assessment. These ratings reflect Haleon's strong environmental, social, and governance practices that extend to all brands, including Lamisil.

Climate Action and Environmental Performance: Haleon achieved strong performance in the Carbon Disclosure Project (CDP) with scores of B for Climate Change, B for Forests, and A- for Water security performance as of 2025. The company achieved 'A' as part of the Supplier Engagement Assessment (SEA) based on performance in governance, targets, Scope 3 emissions, and value chain engagement in the CDP climate change questionnaire. Lamisil's manufacturing and distribution processes align with these environmental standards.

Health Inclusivity and Access: Lamisil supports Haleon's commitment to health inclusivity, ensuring that effective antifungal treatments are accessible to diverse populations worldwide. The brand's availability as an over-the-counter medication helps democratize access to fungal infection treatment, particularly in regions where prescription access may be limited. Lamisil's role in treating common fungal infections like athlete's foot and toenail fungus contributes to global health equity.

Responsible Manufacturing and Supply Chain: Lamisil is manufactured according to Haleon's responsible manufacturing standards, which emphasize environmental compliance, ethical sourcing of raw materials, and sustainable production processes. The company maintains strict quality control measures and environmental standards across its manufacturing facilities in the UK, US, Switzerland, and other international locations, ensuring product safety and environmental responsibility.

Global Health Access and Affordability: Lamisil contributes to Haleon's mission of delivering better everyday health by ensuring access to effective antifungal treatments across diverse global markets. The company maintains pricing strategies that balance affordability with sustainability investments, making fungal infection treatment accessible while supporting environmental and social responsibility initiatives.

Clinical Research and Ethical Standards: Lamisil maintains strict ethical standards in clinical research and product development, ensuring all studies comply with international guidelines and ethical review board requirements. The company's commitment to patient safety includes comprehensive monitoring of adverse effects, transparent reporting of clinical trial results, and ongoing post-market surveillance.

Responsible Packaging and Distribution: Lamisil implements sustainable packaging initiatives focused on reducing environmental impact while maintaining medication safety and efficacy. The company uses recyclable packaging materials where possible, reduces excess packaging, and implements waste reduction programs in distribution and retail operations.

Supply Chain Ethics and Human Rights: Lamisil works with suppliers who meet strict environmental and ethical standards, particularly for pharmaceutical manufacturing practices and labor conditions. The company's supply chain program ensures compliance with pharmaceutical regulations, environmental standards, and business ethics throughout its global supplier network.

Lamisil has received recognition within the pharmaceutical and healthcare industry for its effectiveness in treating fungal infections, innovation in antifungal therapy, and contributions to consumer healthcare accessibility. The brand's long-standing presence in the market and consistent therapeutic efficacy have been acknowledged by medical professionals and healthcare organizations.

Pharmaceutical Excellence Recognition: Lamisil has been acknowledged by healthcare professionals and pharmaceutical organizations for its effectiveness in treating fungal infections, including athlete's foot, jock itch, and nail fungus. The brand's consistent therapeutic performance and safety profile have been recognized as demonstrating excellence in over-the-counter antifungal treatments.

Consumer Healthcare Innovation Awards: As part of Haleon's portfolio, Lamisil has benefited from recognition of Haleon's innovation in consumer healthcare products and sustainable business practices. The company's ability to combine effective pharmaceutical treatments with consumer accessibility has been acknowledged by healthcare industry organizations.

Medical Professional Endorsements: Lamisil has received endorsements from dermatologists and podiatrists for its efficacy in treating common fungal infections. The brand's reliability and consistent performance have made it a recommended treatment option among healthcare professionals for fungal infection management.

Clinical Efficacy and Safety Recognition: Lamisil's active ingredient, terbinafine, has received extensive clinical validation for its effectiveness in treating various fungal infections. The brand's consistent safety profile and efficacy have been acknowledged through regulatory approvals and clinical studies, establishing Lamisil as a scientifically validated treatment option in the antifungal medication market.

Market Leadership in Antifungal Category: Lamisil maintains a strong market position as a leading antifungal brand, competing effectively with both prescription and over-the-counter alternatives. The brand's market leadership is recognized through its established presence in pharmacies and retail outlets worldwide, reflecting consumer trust and healthcare provider confidence in its efficacy and safety profile.

Regulatory Compliance Recognition: Lamisil has received regulatory approvals from major health authorities worldwide, including the FDA, demonstrating its compliance with stringent pharmaceutical standards. These regulatory approvals represent recognition of the brand's quality, safety, and efficacy in treating fungal infections, enhancing its credibility in the healthcare market.

Consumer Trust and Brand Loyalty: Lamisil has built strong consumer trust through consistent performance and reliability in treating fungal infections. The brand's established reputation for efficacy and safety has resulted in high brand loyalty and repeat purchases, representing consumer recognition of its value in treating common fungal conditions.

Healthcare Provider Endorsement: Lamisil is widely recommended by healthcare providers, including dermatologists and podiatrists, for treating various fungal infections. This professional endorsement represents recognition within the medical community of Lamisil's efficacy and appropriateness for treating conditions like athlete's foot, jock itch, and other fungal infections.

Lamisil has maintained a relatively clean safety record since its approval in 1991, benefiting from rigorous clinical testing and regulatory oversight. However, as with all pharmaceutical products, Lamisil has faced some controversies and safety considerations related to potential side effects, regulatory warnings, and market competition issues that have required attention from healthcare providers and regulatory authorities.

FDA Safety Warnings and Precautions: Lamisil has been subject to FDA safety warnings regarding potential side effects, particularly for oral formulations. The FDA requires patients to be warned about potential liver function abnormalities and recommends monitoring of serum transaminases (ALT and AST) before and during treatment. These warnings reflect the importance of patient safety and proper medical supervision when using Lamisil, particularly for oral formulations used in treating nail fungus.

Potential Side Effects and Adverse Reactions: Lamisil has been associated with potential side effects that have required consumer education and healthcare provider awareness. Common side effects include skin irritation, redness, and itching for topical formulations, while oral terbinafine can cause more serious side effects including liver function abnormalities, taste disturbances, and gastrointestinal symptoms. These potential side effects have necessitated comprehensive patient education and monitoring protocols.

Allergic Reaction Concerns: Lamisil carries warnings about potential allergic reactions, including the risk of anaphylaxis in rare cases. Patients with known allergies to terbinafine or other components of Lamisil formulations are advised against using the product. These allergic reaction concerns require careful patient screening and emergency preparedness, representing ongoing safety considerations for the brand.

Liver Function Monitoring Requirements: Oral Lamisil treatment requires liver function monitoring due to potential hepatotoxicity risks. Patients with pre-existing liver conditions or those taking other medications that may affect liver function require special consideration and monitoring. These safety requirements have created complexity in treatment protocols and necessitated close medical supervision.

Drug Interaction Controversies: Lamisil has potential drug interactions that have required careful consideration, particularly with medications that affect liver metabolism. The need to consider potential drug interactions has created complexity in treatment planning, particularly for patients taking multiple medications for various health conditions.

Market Competition and Generic Competition: Lamisil faces competition from generic terbinafine products and other antifungal treatments, which has created market share challenges and pricing pressures. While competition generally benefits consumers through lower prices, it has required Lamisil to maintain its competitive position through brand differentiation and quality assurance.

Over-the-Counter Availability Debates: The availability of Lamisil as an over-the-counter medication has sparked debates about appropriate access versus the need for medical supervision. While increased accessibility benefits consumers, some healthcare providers have expressed concerns about potential misuse or inappropriate treatment without proper medical diagnosis and supervision.

Treatment Duration and Compliance Issues: Lamisil treatment requires specific duration guidelines for different types of fungal infections, and patient compliance with these guidelines can be challenging. Issues related to treatment duration and patient compliance have affected treatment outcomes and required enhanced patient education and support programs.

Regulatory Scrutiny and Labeling Requirements: Lamisil has undergone regulatory scrutiny regarding labeling requirements and patient information. Regulatory agencies have required comprehensive labeling about potential side effects, usage instructions, and contraindications, creating ongoing compliance requirements for the brand.